Elsevier

Seminars in Cancer Biology

Volume 6, Issue 6, December 1995, Pages 357-366
Seminars in Cancer Biology

Augmenting the immunogenicity of carbohydrate tumor antigens

https://doi.org/10.1016/1044-579X(95)90005-5Get rights and content

Abstract

Antibody responses have identified cell surface carbohydrate antigens as potentially immunogenic cancer antigens in a variety of different tumors, but immunization with whole tumor cells or cell lysates has only occasionally induced immune responses against these antigens. Three approaches to further augmenting their immunogenicity have been explored, mixture with immunological adjuvants, synthesis of more immunogenic derivatives and conjugation to immunogenic proteins. Conjugation to proteins such as KLH plus the use of potent adjuvants such as QS-21 proved most immunogenic. Carbohydrate epitopes on gangliosides (GM2 and GD2), neutral glycolipids (Lev and Globo H) and glycoproteins (Lev, Globo H, TF, sTn and Tn) are of special interest. Each of these antigen has been synthesized and conjugated to KLH. Their use in preclinical or clinical vaccination studies has resulted in increased IgM and IgG antibody responses against tumors expressing these antigens. Phase I–II clinical trials in patients with cancer have been initiated with each to optimize immunogenicity. The GM2 vaccine has progressed to Phase III trials and the sTn vaccine to Phase II trials aimed at determining the impact of vaccination on survival.

References (56)

  • PO Livingston

    Approaches to augmenting the immunogenicity of melanoma gangliosides: From Whole melanoma cells to ganglioside-KLH conjugate vaccines

    Immunol Rev

    (1995)
  • V Brichard et al.

    The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas

    J Exp Med

    (1993)
  • PG Coulie et al.

    A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas

    J Exp Med

    (1994)
  • T Wolfel et al.

    A mutated CDK4 allele is recognized by autologous cytolytic T lymphocytes (CTL) in a human melanoma

    Science

    (1995)
  • T Tai et al.

    Immunogenicity of melanoma-associated gangliosides in cancer patients

    Int J Cancer

    (1985)
  • N-KV Cheung et al.

    Gangliosides GD2 specific monoclonal antibody 3F8: A phase I study in patients with neuroblastoma and malignant melanoma

    J Clin Oncol

    (1987)
  • AN Houghton et al.

    Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: A phase I trial in patients with malignant melanoma

  • MN Saleh et al.

    Phase I trial of the murine monoclonal anti-GD2 antibody 14G2a in metastatic melanoma

    Cancer Res

    (1992)
  • GF Springer

    T and Tn. general carcinoma autoantigens

    Science

    (1984)
  • KP O'Boyle et al.

    Immunization of colorectal cancer patients with modified ovine submaxillary gland mucin and adjuvants induces IgM and IgG antibodies to sialvlated Tn

    Cancer Res

    (1992)
  • S Adluri et al.

    Cancer Immunol Immunother

    (1995)
  • SH Itzkowitz et al.

    Sialosvl Tn: A novel mucin antigen associated with prognosis in colorectal cancer patients

    Cancer

    (1990)
  • PYS Fung et al.

    Active specific immunotherapy of a murine mammary adenocarcinoma using a synthetic tumor-associated glycoconjugate

    Cancer Res

    (1990)
  • A Singlial et al.

    Induction of a-N-acetylgalactosamine-O-serine/threonine (Tn) antigen-mediated cellular immune response for active immunotherapy in mice

    Cancer Res

    (1991)
  • RA Ghossein et al.

    Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: clinical implications

    J Clin Oncol

    (1995)
  • PO Livingston et al.

    Approaches to augmenting the immunogenicity of the ganglioside GM2 in mice: Purified GM2 is superior to whole cells

    J Immunol

    (1987)
  • PO Livingston et al.

    Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients

  • PO Livingston et al.

    Comparison of approaches for augmenting the serological response to the Meth A antigen

  • Cited by (0)

    View full text